WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317123

CAS#: 25451-15-4

Description: Felbamate is an anti-epileptic drug used in the treatment of epilepsy. Felbamate has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptors, the relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.

Price and Availability


USD 90
USD 450
USD 2650

USD 150
USD 850
USD 4850

USD 250
USD 1450
USD 6750

Felbamate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317123
Name: Felbamate
CAS#: 25451-15-4
Chemical Formula: C11H14N2O4
Exact Mass: 238.09536
Molecular Weight: 238.24
Elemental Analysis: C, 55.46; H, 5.92; N, 11.76; O, 26.86

Synonym: W-554; W 554; W554; ADD-03055; ADD03055; ADD 03055; Felbamate; brand name: Felbatol; Felbamyl; Taloxa.

IUPAC/Chemical Name: 2-phenylpropane-1,3-diyl dicarbamate


InChi Code: InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)


Technical Data

White to off-white crystalline powder.

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2014 Jul 18;7:CD008295. doi: 10.1002/14651858.CD008295.pub3. Review. PubMed PMID: 25036694.

2: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008295. doi: 10.1002/14651858.CD008295.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD008295. PubMed PMID: 21249704.

3: Tribut O, Bentué-Ferrer D, Verdier MC; le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. [Therapeutic drug monitoring of felbamate]. Therapie. 2010 Jan-Feb;65(1):35-8. doi: 10.2515/therapie/2009068. Epub 2010 Mar 8. Review. French. PubMed PMID: 20205993.

4: Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res. 2006 Oct;71(2-3):89-101. Epub 2006 Aug 4. Review. PubMed PMID: 16889941.

5: Borowicz KK, Piskorska B, Kimber-Trojnar Z, Małek R, Sobieszek G, Czuczwar SJ. Is there any future for felbamate treatment? Pol J Pharmacol. 2004 May-Jun;56(3):289-94. Review. PubMed PMID: 15215558.

6: Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact. 2002 Nov 10;142(1-2):99-117. Review. PubMed PMID: 12399158.

7: Pellock JM. Felbamate. Epilepsia. 1999;40 Suppl 5:S57-62. Review. PubMed PMID: 10530695.

8: Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999 Sep;21(3):225-39. Review. PubMed PMID: 10487399.

9: Brown WM, Aiken SP. Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Crit Rev Neurobiol. 1998;12(3):205-22. Review. PubMed PMID: 9847055.

10: Corradetti R, Pugliese AM. Electrophysiological effects of felbamate. Life Sci. 1998;63(13):1075-88. Review. PubMed PMID: 9763203.

11: Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997 Dec;38(12):1265-9. Review. PubMed PMID: 9578520.

12: Curry WJ, Kulling DL. Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin. Am Fam Physician. 1998 Feb 1;57(3):513-20. Review. PubMed PMID: 9475899.

13: Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin Pharmacokinet. 1997 Sep;33(3):214-24. Review. PubMed PMID: 9314612.

14: Bourgeois BF. Felbamate. Semin Pediatr Neurol. 1997 Mar;4(1):3-8. Review. Erratum in: Semin Pediatr Neurol 1998 Mar;5(1):76. PubMed PMID: 9097361.

15: Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet. 1995 Nov;29(5):341-69. Review. PubMed PMID: 8582119.

16: Pérez-Miranda J, Aguirre J, Parrilla JL, Pérez Miranda M. [Felbamate: perspectives for new antiepileptic treatment]. Rev Neurol. 1995 Nov-Dec;23(124):1220-5. Review. Spanish. PubMed PMID: 8556622.

17: Leppik IE. Felbamate. Epilepsia. 1995;36 Suppl 2:S66-72. Review. PubMed PMID: 8784215.

18: Herranz JL, Arteaga R, Armijo JA. [New antiepileptic drugs: vagabatrin, lamotrigine and felbamate]. Neurologia. 1994 Nov;9(9):410-7. Review. Spanish. PubMed PMID: 7811493.

19: Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol. 1994 Oct;17(5):389-402. Review. PubMed PMID: 9316688.

20: Steinhoff BJ. [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview]. Fortschr Neurol Psychiatr. 1994 Oct;62(10):379-88. Review. German. PubMed PMID: 8001894.